The EU has approved the first medicine for the hereditary Skelleftesjukan. Attrogy (diflunisal) is the first medication in tablet form for the disease and could previously only be obtained on a license, reports Sveriges Radio P4 Västerbotten.
There are approximately 400 people with the disease in Sweden, most of them in the areas around Skellefteå and Piteå.
Skelleftesjukan, or hereditary transthyretin amyloidosis as it is called, is a neurological disease that weakens the body's nerves and organs.
